TY  - JOUR
AU  - Taugner, Julian
AU  - Stamer, Silja
AU  - Hofstetter, Kerstin
AU  - Eze, Chukwuka
AU  - Käsmann, Lukas
AU  - Clasen, Kerstin
AU  - Hartig, Philipp
AU  - Spengler, Werner
AU  - Groß, Thorben
AU  - Manapov, Farkhad
AU  - Belka, Claus
AU  - Niyazi, Maximilian
TI  - Immune checkpoint inhibition alters patterns of failure in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy.
JO  - Journal of cancer research and clinical oncology
VL  - 151
IS  - 12
SN  - 0301-1585
CY  - Heidelberg
PB  - Springer
M1  - DKFZ-2025-02257
SP  - 313
PY  - 2025
AB  - We compared failure patterns in patients with inoperable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy (CRT) alone versus CRT combined with sequential and/or concurrent immune checkpoint inhibitors (CRT-IO).Retrospective real-world data from 221 patients across two German tertiary cancer centers were analyzed. Of these, 74 received CRT-IO, including sequential durvalumab (85
KW  - Humans
KW  - Carcinoma, Non-Small-Cell Lung: therapy
KW  - Carcinoma, Non-Small-Cell Lung: pathology
KW  - Carcinoma, Non-Small-Cell Lung: drug therapy
KW  - Carcinoma, Non-Small-Cell Lung: mortality
KW  - Carcinoma, Non-Small-Cell Lung: immunology
KW  - Female
KW  - Male
KW  - Immune Checkpoint Inhibitors: therapeutic use
KW  - Immune Checkpoint Inhibitors: administration & dosage
KW  - Lung Neoplasms: pathology
KW  - Lung Neoplasms: therapy
KW  - Lung Neoplasms: drug therapy
KW  - Lung Neoplasms: mortality
KW  - Lung Neoplasms: immunology
KW  - Aged
KW  - Middle Aged
KW  - Retrospective Studies
KW  - Chemoradiotherapy: methods
KW  - Neoplasm Staging
KW  - Adult
KW  - Aged, 80 and over
KW  - Treatment Failure
KW  - Nivolumab: administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols: therapeutic use
KW  - Antibodies, Monoclonal
KW  - Chemoradiotherapy (Other)
KW  - Immunotherapy (Other)
KW  - Lung cancer (Other)
KW  - NSCLC (Other)
KW  - Patterns-of-failure (Other)
KW  - Immune Checkpoint Inhibitors (NLM Chemicals)
KW  - Nivolumab (NLM Chemicals)
KW  - durvalumab (NLM Chemicals)
KW  - Antibodies, Monoclonal (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:41175229
DO  - DOI:10.1007/s00432-025-06355-y
UR  - https://inrepo02.dkfz.de/record/305607
ER  -